glp 1 receptor antagonist examples glp-1_analogs [TUSOM The Extracellular Surface of the

The LEADER trial showed that liraglutide reduced the risk of major cardiovascular events in people with type 2 diabetes.[4] Soon after, SUSTAIN-6 demonstrated similar benefits with semaglutide.[5] Then came REWIND, which suggested that cardiovascular protection could extend even to patients without established cardiovascular disease.[6] The SELECT trial made headlines because it showed cardiovascular benefits in people with overweight or obesity who did not have diabetes, a finding that challenged long-held assumptions about who might benefit from these medicines.[7] Most recently, an international trial called SOUL, which tested an oral form of semaglutide, included 788 Indian patients across 32 centres

They play a key role in managing blood glucose levels and controlling appetite

For the general population : L-carnitine can support cardiovascular health in a preventive approach, particularly in regular athletes and those with a family history

Logie, L